| Company Announcements: (reported by the Company) |
|
| Elevator Pitch: | Paradigm Biopharmaceuticals (PAR) listed on the ASX in August 2015. We focus on re-purposing pentosan polysulphate sodium (PPS) for new orthopaedic and respiratory applications. We focus on PPS because this FDA-approved drug has a long history of safety and efficacy in treating interstitial cystitis and deep vein thrombosis. Our patents cover new applications in bone marrow edema (BME) and and the allergic inflammatory response in allergic rhinitis (AR), which is commonly known as ‘Hay Fever’. |
| Category: | Health & biotech |
| URL: | http://paradigmbiopharma.com/ |
| Operational Status: | Active |
| ASX Listing Code (if applicable): | PAR |
| Year of Commencement: | 2014 |
| Address: | Level 2, |
| State: | Victoria |
| Overseas Operations: | No |
| Twitter: | |
| Facebook: | |
| Linkedin: | https://www.linkedin.com/company/paradigm-biopharmaceuticals/ |
| Founders: | |
| Awards won: | |
